Skip to content
Open access · CC-BY via OpenAlex

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

Alexis Moscoso, Michel J. Grothe, Nicholas James Ashton, Thomas K. Karikari, Juan Lantero‐Rodriguez, Anniina Snellman, Marc Suárez‐Calvet, Kaj Blennow, Henrik Zetterberg, Michael Schöll, Alzheimer’s Disease Neuroimaging Initiative, Michael Walter Weiner, Paul Aisen, Ronald Carl Petersen, Clifford R. Jack

JAMA Neurology · 2021 · ▲ 311 citations

Abstract

Importance: Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression in AD remains unclear. Objective: To study the potential of longitudinal plasma p-tau181 measures for assessing neurodegeneration progression and cognitive decline in AD in comparison to plasma neurofilament light chain (NfL), a disease-nonspecific marker of neuronal injury. Design, Setting, and Participants: This longitudinal cohort study included data from the Alzheimer's Disease Neuroimaging Initiative from February 1, 2007, to June 6, 2016. Follow-up blood sampling was performed for up to 8 years. Plasma p-tau181 measurements were performed in 2020. This was a multicentric observational study of 1113 participants, including cognitively unimpaired participants as well as patients with cognitive impairment (mild cognitive impairment and AD dementia). Participants were eligible for inclusion if they had available plasma p-tau181 and NfL measurements and at least 1 fluorine-18-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) or structural magnetic resonance imaging scan performed at the same study visit. Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol. Exposures: Plasma p-tau181 and NfL measured with single-molecule array technology. Main Outcomes and Measures: Longitudinal imaging markers of neurodegeneration (FDG PET and structural magnetic resonance imaging) and cognitive test scores (Preclinical Alzheimer Cognitive Composite and Alzheimer Disease Assessment Scale-Cognitive Subscale with 13 tasks). Data were analyzed from June 20 to August 15, 2020. Results: Of the 1113 participants (mean [SD] age, 74.0 [7.6] years; 600 men [53.9%]; 992 non-Hispanic White participants [89.1%]), a total of 378 individuals (34.0%) were cognitively unimpaired (CU) and 735 participants (66.0%) were cognitively impaired (CImp). Of the CImp group, 537 (73.1%) had mild cognitive impairment, and 198 (26.9%) had AD dementia. Longitudinal changes of plasma p-tau181 were associated with cognitive decline (CU: r = -0.24, P < .001; CImp: r = 0.34, P < .001) and a prospective decrease in glucose metabolism (CU: r = -0.05, P = .48; CImp: r = -0.27, P < .001) and gray matter volume (CU: r = -0.19, P < .001; CImp: r = -0.31, P < .001) in highly AD-characteristic brain regions. These associations were restricted to amyloid-β-positive individuals. Both plasma p-tau181 and NfL were independently associated with cognition and neurodegeneration in brain regions typically affected in AD. However, NfL was also associated with neurodegeneration in brain regions exceeding this AD-typical spatial pattern in amyloid-β-negative participants. Mediation analyses found that approximately 25% to 45% of plasma p-tau181 outcomes on cognition measures were mediated by the neuroimaging-derived markers of neurodegeneration, suggesting links between plasma p-tau181 and cognition independent of these measures. Conclusions and Relevance: Study findings suggest that plasma p-tau181 was an accessible and scalable marker for predicting and monitoring neurodegeneration and cognitive decline and was, unlike plasma NfL, AD specific. The study findings suggest implications for the use of plasma biomarkers as measures to monitor AD progression in clinical practice and treatment trials.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1001/jamaneurol.2020.4986
Canonical
link ↗
Fetched
2026-10-17 MST

Cite this

APA
Moscoso, A., Grothe, M.J., Ashton, N.J., Karikari, T.K., Lantero‐Rodriguez, J., Snellman, A., Suárez‐Calvet, M., Blennow, K., Zetterberg, H., Schöll, M., Initiative, A.D.N., Weiner, M.W., Aisen, P., Petersen, R.C., Jack, C.R., Jagust, W.J., Trojanowki, J.Q., Toga, A.W., Beckett, L.A., &amp; Green, R.C. (2021). Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <em>JAMA Neurology</em>. https://doi.org/10.1001/jamaneurol.2020.4986
Vancouver
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero‐Rodriguez J, Snellman A, et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology. 2021. doi:10.1001/jamaneurol.2020.4986.
BibTeX
@article{alexis2021Longit, title = {Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease}, author = {Alexis Moscoso and Michel J. Grothe and Nicholas James Ashton and Thomas K. Karikari and Juan Lantero‐Rodriguez and Anniina Snellman and Marc Suárez‐Calvet and Kaj Blennow and Henrik Zetterberg and Michael Schöll and Alzheimer’s Disease Neuroimaging Initiative and Michael Walter Weiner and Paul Aisen and Ronald Carl Petersen and Clifford R. Jack and William J. Jagust and John Q. Trojanowki and Arthur W. Toga and Laurel A. Beckett and Robert C. Green and Andrew J. Saykin and John C. Morris and Leslie M. J. Shaw and Zaven S. Khachaturian and Greg Sorensen}, journal = {JAMA Neurology}, year = {2021}, doi = {10.1001/jamaneurol.2020.4986}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings